Zomedica Pharmaceuticals

Rank#9870

Market Cap95.35M

CountryUnited States

Summary

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

History

Zomedica Pharmaceuticals Corp. was incorporated on April 12, 2018 under the laws of the State of Delaware and is a publicly traded company on the Toronto Venture Exchange under the symbol ZOM. The Company trades in the United States on the OTCQB under the symbol ZOMZF.

Mission

Zomedica’s mission is to give veterinarians the solutions that they need to practice their craft with confidence.

Vision

Zomedica strives to be the highest quality provider of products and services that enhance the lives of companion animals and their owners worldwide.

References

https://in.investing.com/equities/zomedica-pharma

https://finance.yahoo.com/quote/ZOM/profile?p=ZOM

https://www.crunchbase.com/organization/zomedica

https://companiesmarketcap.com/

https://www.zomedica.com

Leadership team

Mr. Larry C. Heaton II (Pres & CEO)